0001415889-21-003240.txt : 20210628
0001415889-21-003240.hdr.sgml : 20210628
20210628071526
ACCESSION NUMBER: 0001415889-21-003240
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210624
FILED AS OF DATE: 20210628
DATE AS OF CHANGE: 20210628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RUFFOLO ROBERT R
CENTRAL INDEX KEY: 0001187308
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39746
FILM NUMBER: 211049933
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sigilon Therapeutics, Inc.
CENTRAL INDEX KEY: 0001821323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 474005543
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-336-7540
MAIL ADDRESS:
STREET 1: 100 BINNEY STREET
STREET 2: STE 600
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
form4-06282021_070612.xml
X0306
4
2021-06-24
0001821323
Sigilon Therapeutics, Inc.
SGTX
0001187308
RUFFOLO ROBERT R
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600
CAMBRIDGE
MA
02142
true
false
false
false
Stock Option (Right to Buy)
9.97
2021-06-24
4
A
0
8888
9.97
A
2031-06-23
Common Stock
8888
8888
D
The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022.
/s/ Matthew Kowalsky, Attorney-in-Fact
2021-06-28